MolPharm

Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
 QUICK SEARCH:   [advanced]


     


This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Sun, W.
Right arrow Articles by Kapur, S.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Sun, W.
Right arrow Articles by Kapur, S.

Vol. 63, Issue 2, 456-462, February 2003

In Vivo Evidence for Dopamine-Mediated Internalization of D2-Receptors after Amphetamine: Differential Findings with [3H]Raclopride versus [3H]Spiperone

W. Sun, N. Ginovart, F. Ko, P. Seeman, and S. Kapur

PET Centre, Centre for Addiction and Mental Health, Toronto, Ontario, Canada (W.S., N.G., S.K.); and Departments of Psychiatry (N.G., S.K.) and Pharmacology (W.S., F.K., P.S.), University of Toronto, Ontario, Canada

Competition with endogenous dopamine (DA) is usually invoked to explain changes in [11C]raclopride binding observed after amphetamine administration in animals and humans. This account has recently been questioned because a number of inconsistencies have been reported that contradict it. In the present study, we investigated whether the decrease in [3H]raclopride binding observed in the rat striatum after an amphetamine challenge reflects true competition with endogenous DA or agonist-mediated internalization of D2-receptors. We found that the amphetamine-induced decrease in [3H]raclopride binding is caused by a decrease in D2-receptor density (Bmax) with no change in affinity (Kd). In contrast, in the same tissue, neither the Bmax nor the Kd were affected when measured with [3H]spiperone. Challenge with amphetamine not only decreased the number of D2-receptors but also eliminated the proportion (22%) of receptors usually in the high-affinity state. The addition of Gpp(NH)p had no effect on Bmax, suggesting that these receptors were not just noncompetitively bound with dopamine at the cell-surface. Subcellular fractionation studies showed that amphetamine treatment led to a decrease in radioligand binding in the cell-surface fraction for both [3H]raclopride and [3H]spiperone; however, in the case of [3H]spiperone, this was accompanied by a compensatory increase in binding in the intracellular compartment, whereas no increase was seen with [3H]raclopride. These data suggest that amphetamine releases dopamine, which binds to the high-affinity state of the D2-receptor, leading to its sequestration in some intracellular compartment; in this compartment, sequestered receptors are inaccessible to [3H]raclopride binding but can still be bound by [3H]spiperone.


Copyright © 2003 by The American Society for Pharmacology and Experimental Therapeutics



This article has been cited by other articles:


Home page
Theory PsychologyHome page
J. A. den Boer, A.A.T. S. Reinders, and G. Glas
Special Section: On Looking Inward: Revisiting the Role of Introspection in Neuroscientific and Psychiatric Research
Theory Psychology, June 1, 2008; 18(3): 380 - 403.
[Abstract] [PDF]


Home page
Mol. Pharmacol.Home page
C. H. So, G. Varghese, K. J. Curley, M. M. C. Kong, M. Alijaniaram, X. Ji, T. Nguyen, B. F. O'Dowd, and S. R. George
D1 and D2 Dopamine Receptors Form Heterooligomers and Cointernalize after Selective Activation of Either Receptor
Mol. Pharmacol., September 1, 2005; 68(3): 568 - 578.
[Abstract] [Full Text] [PDF]


Home page
BrainHome page
R. de la Fuente-Fernandez, V. Sossi, Z. Huang, S. Furtado, J.-Q. Lu, D. B. Calne, T. J. Ruth, and A. J. Stoessl
Levodopa-induced changes in synaptic dopamine levels increase with progression of Parkinson's disease: implications for dyskinesias
Brain, December 1, 2004; 127(12): 2747 - 2754.
[Abstract] [Full Text] [PDF]


Home page
J. Neurosci.Home page
D. H. Zald, I. Boileau, W. El-Dearedy, R. Gunn, F. McGlone, G. S. Dichter, and A. Dagher
Dopamine Transmission in the Human Striatum during Monetary Reward Tasks
J. Neurosci., April 28, 2004; 24(17): 4105 - 4112.
[Abstract] [Full Text] [PDF]




Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
 Molecular Interventions Drug Metabolism and Disposition

Copyright © 2003 by the American Society for Pharmacology and Experimental Therapeutics